Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.57 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294850 | 0.85 | MAP2K1 (0.49) | MAP2K1JAK2JAK1TYK2JAK3 | |
| SCHEMBL12423782 | 0.80 | MAP2K1 (0.57) | MAP2K1MAP2K2 | |
| SCHEMBL391574 | 0.79 | MAP2K1 (0.53) | MAP2K1MAP2K2BRAF | |
| SCHEMBL16103842 | 0.77 | MAP2K1 (0.60) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL16070018 | 0.77 | MAP2K1 (0.60) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL13522214 | 0.76 | MAP2K1 (0.60) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL1579837 | 0.75 | MAP2K1 (0.70) | MAP2K1MAP2K2IDO1 | |
| SCHEMBL387833 | 0.75 | MAP2K1 (0.51) | MAP2K1MAP2K2BRAF | |
| SCHEMBL391025 | 0.74 | MAP2K1 (0.47) | MAP2K1MAP2K2BRAF | |
| SCHEMBL10251094 | 0.74 | MAP2K1 (0.48) | MAP2K1MAP2K2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | claimed |
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003025-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENENTECH, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | MAP2K7, MAP3K1, MAP3K5 | MAP2K1 11/4885JAK2 158/4885JAK1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.